Which Myriad test is used to determine HRD status?

Which Myriad test is used to determine HRD status?

• A. MyChoice CDx
• B. HRD Panel
• C. OncoVantage
• D. BRACAnalysis

Answer: (A)

Homologous recombination deficiency (HRD) is a tumor feature that indicates impaired DNA repair via the HR pathway and helps predict response to PARP inhibitors. To determine HRD status, a test must assess genome-wide instability in addition to any BRCA mutation status. MyChoice CDx is designed for this purpose: it provides BRCA1/2 mutation status and a composite HRD score derived from genomic instability markers, such as loss of heterozygosity, telomeric imbalance, and large-scale state transitions. A high HRD score classifies the tumor as HRD-positive, guiding the use of PARP inhibitor therapy. Other options either focus solely on germline BRCA testing or are not the standard Myriad assay used to determine HRD status.

Homologous recombination deficiency (HRD) is a tumor feature that indicates impaired DNA repair via the HR pathway and helps predict response to PARP inhibitors. To determine HRD status, a test must assess genome-wide instability in addition to any BRCA mutation status. MyChoice CDx is designed for this purpose: it provides BRCA1/2 mutation status and a composite HRD score derived from genomic instability markers, such as loss of heterozygosity, telomeric imbalance, and large-scale state transitions. A high HRD score classifies the tumor as HRD-positive, guiding the use of PARP inhibitor therapy. Other options either focus solely on germline BRCA testing or are not the standard Myriad assay used to determine HRD status.